POSSIBILITIES AND LIMITS OF THERAPY IN A CASE OF HYPOCHONDROPLASIA

Revista Romana de PEDIATRIE | Volumul LXIII, Nr. 1, An 2014

ISSN 1454-0398 | e-ISSN 2069-6175
ISSN-L 1454-0398
DOI: 10.37897/RJP

National Awards “Science and Research”

NEW! RJP has announced the annually National Award for "Science and Research" for the best scientific articles published throughout the year in the official journal.

ICMJE- Recommendations

Read the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals.

Promoting Global Health

The published medical research literature is a global public good. Medical journal editors have a social responsibility to promote global health by publishing, whenever possible, research that furthers health worldwide.

Monica Alexoae, Aurica Rugina, Evelina Moraru and Ileana Ioniuc

ABSTRACT

Hypocondroplasia is an autosomal dominant genetic disease caused by mutations in the receptor 3 of the fibroblast growth factor gene. The short stature’s negative impact on quality of life can be improved by early diagnosis and prompt recombinant growth hormone therapy. The authors present the case of a teenager who lost the chance of this therapy because of a late diagnosis.

Keywords: hypochondroplasia, short stature, growth hormone.

Full text | PDF